Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 7, 2004, Pages 605-611

  Fenyvesia, Tivadar ^a   Jörg, Ingrid ^a   Weiss, Christel ^a   Harenberg, Job ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Activated partial thromboplastin time; Additive effect; Direct thrombin inhibitors; Laboratory monitoring; Reagent effect; Vitamin K antagonist

Indexed keywords

ANTIVITAMIN K; ARGATROBAN; HEPARIN; HEPARIN DERIVATIVE; LEPIRUDIN; MELAGATRAN; PHENPROCOUMON; REAGENT; THROMBIN INHIBITOR; THROMBOPLASTIN;

ACCURACY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG EFFECT; HUMAN; LABORATORY TEST; MULTIVARIATE ANALYSIS; NORMAL VALUE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ANTICOAGULANTS; BLOOD COAGULATION; DRUG MONITORING; HUMANS; PARTIAL THROMBOPLASTIN TIME; PHENPROCOUMON; VITAMIN K;

EID: 5644285266     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200409000-00012     Document Type: Article

References (34)

1. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, Maruyama A. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamid portion. Biochem Biophys Res Commun 1982; 101:440-446.
2. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79:110-118.
3. Fenton JW, Villanueva GB, Ofosu FA, Maraganore JM. Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasia 1991; 21(suppl 1):27-31.
4. Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28:425-430.
5. Harder S, Graff J, Klinkhardt U, von Hentig N, Walenga JM, Watanabe H, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time and ecarin clotting time. Thromb Haemost 2004; 91:1137-1145.
6. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmstrom M et al. Pharmacokirtetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor in patients with acute DVT. Thromb Haemost 1999; 81:358-363.
7. Wahlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep venous thrombosis. Thromb Res 2002; 107:93-99.
8. Kaiser B, Fareed J, Walenga JM, Hoppenstaedt D, Markwardt F. In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood. Thromb Res 1991; 64:589-596.
9. Kitchen F, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996; 75:734-739.
10. Preston E. The Control of Anticoagulant Therapy: Current Dilemmas [http://www.nus.edu.sg/ishapd/1996/013.pdf].
11. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al., for the HIT Investigators Group. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 1999; 99:73-80.
12. Harenberg J, Huhle G, Piazolo, L Wang LU, Heene DL. Anticoagulation in patients with heparin-induced thrombocytopenia type II. Semin Thromb Hemost 1997; 23:189-196.
13. Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23:503-516.
14. Harenberg J, Jörg I, Fenyvesi T. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Isr Med Assoc J 2002; 4:1003-1005.
15. Schulman S, Wahlander K, Lundström T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349:1713-1721.
16. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Liebermann JR, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind study. J Thromb Haemost 2003; 1:2119-2130.
17. Walenga JM, Fasanella AR, Iqbal O, Hoppenstaedt D, Sarfraz A, Wallis D, Bakhos M. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999; 25(suppl 1):61-66.
18. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban [e-publish ahead of print]. Ann Pharmacother 2004; 38:25-29.
19. Gustafsson D, Nystrom J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101:171-181.
20. Thomson JM, Taberner DA, Poller L. Automation and prothrombin time: a United Kingdom field Study of two widely used coagulometers. J Clin Pathol 1990; 43:679-684.
21. Fenyvesi T, Jörg I, Weiss C, Harenberg J. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Thromb Res 2003, 111:89-94.
22. Stone SR, Braun PJ, Hofsteenge J. Identification of regions of α-thrombin involved in its interaction with thrombin. Biochemistry 1987; 26: 4617-4624.
23. Nilsson T, Sjöling-Ericksson A, Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human a-thrombin. J Enzyme Inhib 1988; 13:11-29.
24. van den Besselaar AM, Sturk A, Reijnierse GL. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges. Thromb Res 2002; 107:235-240.
25. Ip BK, Thomson AR, Moriarty HAT. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Pathology 2001; 33:347-352.
26. Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving. Arch Intern Med 1998; 158:1140-1143.
27. Baumann P, Heuck CC. Simulation of the extrinsic pathway of the plasrratic clotting system. Haemostasis 1991; 21:329-337.
28. Walenga JM, Hoppenstaedt D, Koza M, Wallock M, Pifarre R, Fareed J. Laboratory assays for the evaluation of recombinant hirudin. Haemostasis 1991; 21(suppl 1):49-63.
29. Nilsson T, Sjoling-Ericksson A, Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin. J Enzyme Inhib 1998; 13:11-29.
30. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25:4622-4628.
31. Johnson BC. Post-translational carboxylation of preprothrombin. Mol Cell Biochem 1981; 38:77-121.
32. Fenyvesi T, Jörg I, Harenberg J. Influence of lepirudin, argatroban, and melayatran on prothrombin time and additional effect of oral anti-coagulation. Clin Chem 2002; 48:1791-1794.
33. Basu D, Gallus A, Hirsh J, Cade JF. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287:324-327.
34. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin ratio to establish a therapeutic range for unfractionated heparin. J Invasive Cardiol 2000; 12(suppl F):27F-32F.